OncoMatch/Clinical Trials/NCT06698003
A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1
Is NCT06698003 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Mogamulizumab for t-cell leukemia/lymphoma, adult.
Treatment: Mogamulizumab — The purpose of this study is to find out whether the study drug mogamulizumab is effective in preventing the development of adult T-cell leukemia/lymphoma (ATL) in people who are at higher risk for this type of cancer because they are infected with the HTLV-1 virus and because of changes seen in some of their immune system cells called T-cells.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Acute Myeloid Leukemia
Prior therapy
Cannot have received: immunosuppressant
Prior treatment with immunosuppressants or interferon alpha products within 6 months prior to the date of enrollment
Cannot have received: interferon alpha
Prior treatment with immunosuppressants or interferon alpha products within 6 months prior to the date of enrollment
Cannot have received: other study drugs
Prior treatment with other study drugs within 4 months prior to giving informed consent
Lab requirements
Blood counts
Neutrophil count ≥1000/mm3 (unless ethnic neutropenia); Platelets ≥100,000/mm3; Hemoglobin ≥9.0 g/dL
Kidney function
Serum creatinine ≤1.5x ULN
Liver function
AST ≤1.5x ULN; ALT ≤1.5x ULN; Total bilirubin ≤1.5x ULN
Cardiac function
Blood oxygen saturation (SpO2) ≥90%; ECG: No abnormal findings requiring treatment
Primary organ functions are stable * Neutrophil count: ≥ 1000/mm3, unless patient has diagnosis of ethnic neutropenia * Platelets: ≥100,000/mm3 * Hemoglobin: ≥9.0 g/dL * Serum aspartate aminotransferase (AST): ≤1.5x upper limit of normal (ULN) * Alanine aminotransferase (ALT): ≤1.5x ULN * Total bilirubin: ≤1.5x ULN * Serum creatinine (Cr): ≤1.5x ULN * Blood oxygen saturation (SpO2): ≥90% * Electrocardiogram (ECG): No abnormal findings requiring treatment are observed
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering at Basking Ridge (All protocol activities) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (All protocol activities) · Middletown, New Jersey
- Memorial Sloan Kettering Bergen (All Protocol Activities) · Montvale, New Jersey
- Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (All protocol activities) · Commack, New York
- Memorial Sloan Kettering Westchester (All protocol activities) · Harrison, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify